Josianne Nunes Carriço,Catarina Inês Gonçalves,Asma Al-Naama,Najeeb Syed,José Maria Aragüés,Margarida Bastos,Fernando Fonseca,Teresa Borges,Bernardo Dias Pereira,Duarte Pignatelli,Davide Carvalho,Filipe Cunha,Ana Saavedra,Elisabete Rodrigues,Joana Saraiva,Luisa Ruas,Nuno Vicente,João Martin Martins,Adriana De Sousa Lages,Maria João Oliveira,Cíntia Castro-Correia,Miguel Melo,Raquel Gomes Martins,Joana Couto,Carolina Moreno,Diana Martins,Patrícia Oliveira,Teresa Martins,Sofia Almeida Martins,Olinda Marques,Carla Meireles,António Garrão,Cláudia Nogueira,Carla Baptista,Susana Gama-de-Sousa,Cláudia Amaral,Mariana Martinho,Catarina Limbert,Luisa Barros,Inês Henriques Vieira,Teresa Sabino,Luís R Saraiva,Manuel Carlos Lemos

Abstract:Study question: What is the contribution of genetic defects in Portuguese patients with congenital hypogonadotropic hypogonadism (CHH)? Summary answer: Approximately one-third of patients with CHH were found to have a genetic cause for their disorder, with causal pathogenic and likely pathogenic germline variants distributed among 10 different genes; cases of oligogenic inheritance were also included. What is known already: CHH is a rare and genetically heterogeneous disorder characterized by deficient production, secretion, or action of GnRH, LH, and FSH, resulting in delayed or absent puberty, and infertility. Study design size duration: Genetic screening was performed on a cohort of 81 Portuguese patients with CHH (36 with Kallmann syndrome and 45 with normosmic hypogonadotropic hypogonadism) and 263 unaffected controls. Participants/materials setting methods: The genetic analysis was performed by whole-exome sequencing followed by the analysis of a virtual panel of 169 CHH-associated genes. The main outcome measures were non-synonymous rare sequence variants (population allele frequency <0.01) classified as pathogenic, likely pathogenic, and variants of uncertain significance (VUS). Main results and the role of chance: A genetic cause was identified in 29.6% of patients. Causal pathogenic and likely pathogenic variants were distributed among 10 of the analysed genes. The most frequently implicated genes were GNRHR, FGFR1, ANOS1, and CHD7. Oligogenicity for pathogenic and likely pathogenic variants was observed in 6.2% of patients. VUS and oligogenicity for VUS variants were observed in 85.2% and 54.3% of patients, respectively, but were not significantly different from that observed in controls. Large scale data: N/A. Limitations reasons for caution: The identification of a large number of VUS presents challenges in interpretation and these may require reclassification as more evidence becomes available. Non-coding and copy number variants were not studied. Functional studies of the variants were not undertaken. Wider implications of the findings: This study highlights the genetic heterogeneity of CHH and identified several novel variants that expand the mutational spectrum of the disorder. A significant proportion of patients remained without a genetic diagnosis, suggesting the involvement of additional genetic, epigenetic, or environmental factors. The high frequency of VUS underscores the importance of cautious variant interpretation. These findings contribute to the understanding of the genetic architecture of CHH and emphasize the need for further studies to elucidate the underlying mechanisms and identify additional causes of CHH. Study funding/competing interests: This research was funded by the Portuguese Foundation for Science and Technology (grant numbers PTDC/SAU-GMG/098419/2008, UIDB/00709/2020, CEECINST/00016/2021/CP2828/CT0002, and 2020.04924.BD) and by Sidra Medicine-a member of the Qatar Foundation (grant number SDR400038). The authors declare no competing interests.

Knockout mice with pituitary malformations help identify human cases of hypopituitarism

Exome Sequencing Has a High Diagnostic Rate in Sporadic Congenital Hypopituitarism and Reveals Novel Candidate Genes

Congenital Hypopituitarism Due to Novel Compound Heterozygous POU1F1 Gene Mutation: A Case Report and Review of the Literature

Clinical characteristics and molecular genetic analysis of a cohort with idiopathic congenital hypogonadism

Allelic Variants in Established Hypopituitarism Genes Expand Our Knowledge of the Phenotypic Spectrum

Mutations in phospholipase C eta-1 (PLCH1) are associated with holoprosencephaly

Modeling the complex etiology of holoprosencephaly in mice

Temporal Analysis of Pituitary Transcriptional Dynamics in Mice Models of Hypopituitarism During Postnatal Development

Mutations in KEOPS-complex Genes Cause Nephrotic Syndrome with Primary Microcephaly

Genetic architecture of congenital hypogonadotropic hypogonadism: insights from analysis of a Portuguese cohort

Integrated clinical and omics approach to rare diseases: novel genes and oligogenic inheritance in holoprosencephaly

Standardizing CRISPR-Cas13 knockdown technique to investigate the role of cdh2 gene in pituitary development through growth hormone expression and transcription factors

The molecular basis of hypoprolactinaemia

Expression of the Sonic hedgehog (SHH ) gene during early human development and phenotypic expression of new mutations causing holoprosencephaly.

Diagnosis and management of congenital hypopituitarism in children

A Novel Splice-Site Deletion in the POU1F1 Gene Causes Combined Pituitary Hormone Deficiency in Multiple Sudanese Pedigrees

Trio-based whole exome sequencing in patients with ectopic posterior pituitary

Panel testing for the molecular genetic diagnosis of congenital hypogonadotropic hypogonadism – a clinical perspective

Pontocerebellar hypoplasia type 1: clinical spectrum and relevance of EXOSC3 mutations

Identification of disease-relevant modulators of the SHH pathway in the developing brain

Knockout mice are an important tool for human monogenic heart disease studies